Posted by Social Science Research Network
Five Arguments Laid to Rest after Actavis
ABSTRACT: The Supreme Court’s decision in FTC v. Actavis has received widespread attention for its antitrust analysis of settlements by which brand-name drug companies pay generics to delay entering the market. Much of the attention has focused on the continued enforcement of these “reverse payment” agreements and the logistics of applying the Court’s rule-of-reason analysis. Less attention has been paid to the watershed nature of the decision in rejecting pro-settlement arguments offered by the settling parties and adopted by the federal appellate courts.
This article catalogs the arguments that the settling parties offered, and the majority of appellate courts adopted, in upholding the agreements. It highlights their prevalence before Actavis and their rejection in the opinion. The arguments concern: (1) the scope of the patent, (2) the importance of settlements, (3) the consequence of large payments, (4) the likelihood of settlement without payment, and (5) the presence of multiple generic challengers.
The Actavis opinion was crucial in eliminating (or at a minimum dramatically reducing) the effect of these arguments, which had the potential to immunize reverse-payment settlements from antitrust review. In rejecting the arguments and ensuring a robust role for antitrust, Actavis was a momentous decision.
Featured News
EU to Scrutinize Telecom Italia’s Network Sale to KKR
May 8, 2024 by
CPI
Turkey Hits Meta with $37.20 Million Fine Over Data-Sharing Practices
May 8, 2024 by
CPI
Google Seeks Dismissal of UK Suit Over Alleged Anti-Competitive Practices
May 8, 2024 by
CPI
Redfin Settles $9.2M Commission Inflation Lawsuits
May 7, 2024 by
CPI
DOJ Supports Colorado’s Efforts to Block Kroger-Albertsons Merger
May 7, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI